What does this research mean for the field?

Allele-specific KRAS mutations dictate distinct mechanisms of adaptive resistance to the RAS(ON) inhibitor daraxonrasib, enabling the rational selection of targeted salvage therapies such as trametinib in pancreatic cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To determine whether distinct KRAS alleles dictate specific adaptive resistance mechanisms to the multi-selective RAS inhibitor daraxonrasib and whether these pathways can be therapeutically targeted.

August 29, 2026Cancer ResearchOpen Access

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

To determine whether distinct KRAS alleles dictate specific adaptive resistance mechanisms to the multi-selective RAS inhibitor daraxonrasib and whether these pathways can be therapeutically targeted.
Investigated resistance pathways to daraxonrasib (RMC-6236) across KRASG12D and KRASG12R pancreatic ductal adenocarcinoma preclinical models.
Performed molecular profiling and rapid 3D-bioprinted patient-derived tumoroid drug sensitivity testing on tissue from a clinical case of acquired resistance.
KRASG12R resistance was driven by EGFR/RASWT-GTP signaling bypass, conferring vulnerability to trametinib, whereas KRASG12D resistance preserved mutant signaling through loss of cyclophilin A.
A patient with KRASG12R pancreatic cancer progressing after 10 months of daraxonrasib achieved ~5 months of disease control on sixth-line trametinib combination therapy and an overall survival of 40 months.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Translational study uncovers allele-specific daraxonrasib resistance mechanisms in pancreatic cancer, demonstrating that tailored salvage therapy can overcome resistance and extend survival.

Cite This Study

Dorbin et al. (2026) studied this question.

synapsesocial.com/papers/6a9299958e5d7d1fc0c1192a https://doi.org/10.1158/0008-5472.can-26-1181

View Full Paper

Ask AI

Bookmark

Implication

Translational study uncovers allele-specific daraxonrasib resistance mechanisms in pancreatic cancer, demonstrating that tailored salvage therapy can overcome resistance and extend survival.

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider